{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alirocumab+SAR236553", "query": { "intervention": "Alirocumab SAR236553" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 36, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alirocumab+SAR236553&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T08:45:26.895Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01730040", "title": "Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 355, "start_date": "2012-10", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-08-31", "last_synced_at": "2026-09-29T08:45:26.895Z", "location_count": 56, "location_summary": "Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01730040" }, { "nct_id": "NCT01954394", "title": "Open Label Study of Long Term Safety Evaluation of Alirocumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Lipid-Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 986, "start_date": "2013-12-17", "completion_date": "2017-06-30", "has_results": true, "last_update_posted_date": "2018-07-24", "last_synced_at": "2026-09-29T08:45:26.895Z", "location_count": 44, "location_summary": "Huntsville, Alabama • Tempe, Arizona • Bell Gardens, California + 39 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Bell Gardens", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01954394" }, { "nct_id": "NCT01644474", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo (for Alirocumab)", "type": "DRUG" }, { "name": "Placebo (for Ezetimibe)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2012-07", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2015-11-06", "last_synced_at": "2026-09-29T08:45:26.895Z", "location_count": 3, "location_summary": "Overland Park, Kansas • Cincinnati, Ohio • Richmond, Virginia", "locations": [ { "city": "Overland Park", "state": "Kansas" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644474" }, { "nct_id": "NCT01161082", "title": "Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "REGN727(SAR236553)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 72, "start_date": "2010-06", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2015-01-27", "last_synced_at": "2026-09-29T08:45:26.895Z", "location_count": 2, "location_summary": "Cincinnati, Ohio • Knoxville, Tennessee", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01161082" }, { "nct_id": "NCT01288469", "title": "Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Placebo (for atorvastatin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 92, "start_date": "2011-01", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2015-09-24", "last_synced_at": "2026-09-29T08:45:26.895Z", "location_count": 20, "location_summary": "Mesa, Arizona • Tucson, Arizona • Los Angeles, California + 14 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Doral", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01288469" }, { "nct_id": "NCT03415178", "title": "Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "Alirocumab SAR236553", "type": "DRUG" }, { "name": "Current auto-injector device (AI)", "type": "DEVICE" }, { "name": "New auto-injector device (SYDNEY)", "type": "DEVICE" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2018-03-29", "completion_date": "2018-08-09", "has_results": true, "last_update_posted_date": "2019-09-09", "last_synced_at": "2026-09-29T08:45:26.895Z", "location_count": 13, "location_summary": "Los Angeles, California • Jacksonville, Florida • Ponte Vedra, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Ponte Vedra", "state": "Florida" }, { "city": "Wellington", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03415178" }, { "nct_id": "NCT01026597", "title": "Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "REGN727", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2009-11", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2015-01-27", "last_synced_at": "2026-09-29T08:45:26.895Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01026597" }, { "nct_id": "NCT01623115", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Lipid Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 486, "start_date": "2012-07", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-02-08", "last_synced_at": "2026-09-29T08:45:26.895Z", "location_count": 26, "location_summary": "Bell Gardens, California • Long Beach, California • Los Angeles, California + 21 more", "locations": [ { "city": "Bell Gardens", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01623115" }, { "nct_id": "NCT01926782", "title": "Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Alirocumab", "type": "DRUG" }, { "name": "Statin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 803, "start_date": "2013-09", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2017-03-21", "last_synced_at": "2026-09-29T08:45:26.895Z", "location_count": 49, "location_summary": "Chandler, Arizona • Goodyear, Arizona • Carmichael, California + 46 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Carmichael", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "West Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01926782" }, { "nct_id": "NCT02585778", "title": "Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Lipid-Modifying Therapy (LMT)", "type": "DRUG" }, { "name": "Antihyperglycemic Drug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 517, "start_date": "2015-10-23", "completion_date": "2017-04-03", "has_results": true, "last_update_posted_date": "2018-05-17", "last_synced_at": "2026-09-29T08:45:26.895Z", "location_count": 29, "location_summary": "Encino, California • Fresno, California • Oakland, California + 25 more", "locations": [ { "city": "Encino", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Loveland", "state": "Colorado" }, { "city": "Atlantis", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02585778" } ] }